DalsnaFinance

Perspective Therapeutics Inc $CATX

Health Care

Russell 2000 Washington
Create a scorecard
$2.26
-0.04 (-1.74%)
As of Oct 22, 2026, 9:32 PM EDT
Price history
Loading chart…

Perspective Therapeutics Inc (CATX) is trading down at $2.26 (-1.74%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

Perspective Therapeutics Inc revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$10.1M−$46.5M−$103.1MFY2016 revenue: $4.77MFY2016 net income: −$4.71M · Net margin −98.8%'16FY2017 revenue: $4.76MFY2017 net income: −$6.16M · Net margin −129.4%'17FY2018 revenue: $5.92MFY2018 net income: −$6.70M · Net margin −113.1%'18FY2019 revenue: $7.31MFY2019 net income: −$5.14M · Net margin −70.3%'19FY2020 revenue: $9.68MFY2020 net income: −$3.45M · Net margin −35.6%'20FY2021 revenue: $10.1MFY2021 net income: −$3.39M · Net margin −33.7%'21FY2022 revenue: $0FY2022 net income: −$10.8M'22FY2023 revenue: $1.43MFY2023 net income: −$46.5M · Net margin −3243.2%'23FY2024 net income: −$79.3M'24FY2025 net income: −$103.1M'25−100%−75%−50%−25%0%FY2016 net margin: −98.8%FY2017 net margin: −129.4% (off the scale, which stops at −100.0%)FY2018 net margin: −113.1% (off the scale, which stops at −100.0%)FY2019 net margin: −70.3%FY2020 net margin: −35.6%FY2021 net margin: −33.7%FY2023 net margin: −3243.2% (off the scale, which stops at −100.0%)
Perspective Therapeutics Inc annual financial statements
FY2016Jun 2016FY2017Jun 2017FY2018Jun 2018FY2019Jun 2019FY2020Jun 2020FY2021Jun 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$4.77M$4.76M$5.92M$7.31M$9.68M$10.1M$0$1.43M——
Growth (year over year)+3.5%−0.2%+24.4%+23.5%+32.3%+3.9%−100.0%———
Gross profit$129.0K$838.0K$1.84M$3.05M$5.12M$5.12M$0$1.43M——
Gross margin2.7%17.6%31.1%41.7%52.9%50.9%—100.0%——
Operating income−$5.08M−$6.31M−$6.73M−$5.25M−$3.48M−$3.45M−$8.67M−$40.9M−$90.9M−$113.6M
Operating margin−106.6%−132.5%−113.6%−71.8%−35.9%−34.3%—−2855.0%——
Net income−$4.71M−$6.16M−$6.70M−$5.14M−$3.45M−$3.39M−$10.8M−$46.5M−$79.3M−$103.1M
Net margin−98.8%−129.4%−113.1%−70.3%−35.6%−33.7%—−3243.2%——
EPS (diluted)−$0.09−$0.11−$0.12−$0.08−$0.05−$0.03—−$1.74−$1.23−$1.40
Balance sheet
Cash and equivalents$10.1M$5.93M$2.60M$5.33M$2.39M$63.8M$21.0M$9.24M$61.6M$30.6M
Total assets$18.1M$12.3M$7.46M$9.42M$8.70M$70.4M$58.1M$97.9M$341.1M$267.0M
Total liabilities$1.70M$1.67M$2.42M$1.74M$2.98M$3.01M$3.45M$22.7M$50.4M$59.9M
Long-term debt———————$1.73M$1.68M$1.63M
Shareholders' equity$16.4M$10.6M$5.03M$7.68M$5.72M$67.4M$54.6M$75.2M$290.7M$207.0M
Cash flow
Operating cash flow−$3.88M−$5.71M−$5.71M−$5.05M−$3.64M−$2.84M−$10.4M−$36.9M−$18.3M−$82.5M
Capital expenditure$479.0K$549.0K$337.0K$444.0K$273.0K$381.0K$282.0K$1.07M$54.4M$12.7M
Free cash flow−$4.36M−$6.26M−$6.05M−$5.49M−$3.91M−$3.22M−$10.7M−$38.0M−$72.7M−$95.2M

From Perspective Therapeutics Inc's 10-K, 10-KT and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Perspective Therapeutics Inc

Headquarters
Seattle, Washington From SEC filings, Oct 2026

Recent News (1)

More Health Care stocks

Browse all companies →